Magnetic nanoparticle hyperthermia enhances radiation therapy: A study in mouse models of human prostate cancer

Anilchandra Attaluri, Sri Kamal Kandala, Michele Wabler, Haoming Zhou, Christine Cornejo, Michael Armour, Mohammad Hedayati, Yonggang Zhang, Theodore DeWeese, Cila Herman, Robert Ivkov

Research output: Contribution to journalArticle

Abstract

Purpose: We aimed to characterise magnetic nanoparticle hyperthermia (mNPH) with radiation therapy (RT) for prostate cancer. Methods: Human prostate cancer subcutaneous tumours, PC3 and LAPC-4, were grown in nude male mice. When tumours measured 150 mm3 magnetic iron oxide nanoparticles (MIONPs) were injected into tumours to a target dose of 5.5 mg Fe/cm3 tumour, and treated 24 h later by exposure to alternating magnetic field (AMF). Mice were randomly assigned to one of four cohorts to characterise (1) intratumour MIONP distribution, (2) effects of variable thermal dose mNPH (fixed AMF peak amplitude 24 kA/m at 160 ± 5 kHz) with/without RT (5 Gy), (3) effects of RT (RT5: 5 Gy; RT8: 8 Gy), and (4) fixed thermal dose mNPH (43 °C for 20 min) with/without RT (5 Gy). MIONP concentration and distribution were assessed following sacrifice and tissue harvest using inductively coupled plasma mass spectrometry (ICP-MS) and Prussian blue staining, respectively. Tumour growth was monitored and compared among treated groups. Results: LAPC-4 tumours retained higher MIONP concentration and more uniform distribution than did PC3 tumours. AMF power modulation provided similar thermal dose for mNPH and combination therapy groups (CEM43: LAPC-4: 33.6 ± 3.4 versus 25.9 ± 0.8, and PC3: 27.19 ± 0.7 versus 27.50 ± 0.6), thereby overcoming limitations of MIONP distribution and yielding statistically significant tumour growth delay. Conclusion: PC3 and LAPC-4 tumours represent two biological models that demonstrate different patterns of nanoparticle retention and distribution, offering a model to make comparisons of these effects for mNPH. Modulating power for mNPH offers potential to overcome limitations of MIONP distribution to enhance mNPH.

Original languageEnglish (US)
Pages (from-to)359-374
Number of pages16
JournalInternational Journal of Hyperthermia
Volume31
Issue number4
DOIs
StatePublished - Jun 1 2015

Fingerprint

Nanoparticles
Prostatic Neoplasms
Fever
Radiotherapy
Neoplasms
Magnetic Fields
Hot Temperature
Biological Models
Group Psychotherapy
Growth
Nude Mice
ferric oxide
Mass Spectrometry
Staining and Labeling

Keywords

  • Hyperthermia
  • Magnetic nanoparticles
  • Prostate cancer
  • Radiation therapy
  • Radiosensitiser

ASJC Scopus subject areas

  • Cancer Research
  • Physiology
  • Radiological and Ultrasound Technology
  • Physiology (medical)

Cite this

Magnetic nanoparticle hyperthermia enhances radiation therapy : A study in mouse models of human prostate cancer. / Attaluri, Anilchandra; Kandala, Sri Kamal; Wabler, Michele; Zhou, Haoming; Cornejo, Christine; Armour, Michael; Hedayati, Mohammad; Zhang, Yonggang; DeWeese, Theodore; Herman, Cila; Ivkov, Robert.

In: International Journal of Hyperthermia, Vol. 31, No. 4, 01.06.2015, p. 359-374.

Research output: Contribution to journalArticle

Attaluri, Anilchandra ; Kandala, Sri Kamal ; Wabler, Michele ; Zhou, Haoming ; Cornejo, Christine ; Armour, Michael ; Hedayati, Mohammad ; Zhang, Yonggang ; DeWeese, Theodore ; Herman, Cila ; Ivkov, Robert. / Magnetic nanoparticle hyperthermia enhances radiation therapy : A study in mouse models of human prostate cancer. In: International Journal of Hyperthermia. 2015 ; Vol. 31, No. 4. pp. 359-374.
@article{342b688ce0b14fb69767caeaddd6597c,
title = "Magnetic nanoparticle hyperthermia enhances radiation therapy: A study in mouse models of human prostate cancer",
abstract = "Purpose: We aimed to characterise magnetic nanoparticle hyperthermia (mNPH) with radiation therapy (RT) for prostate cancer. Methods: Human prostate cancer subcutaneous tumours, PC3 and LAPC-4, were grown in nude male mice. When tumours measured 150 mm3 magnetic iron oxide nanoparticles (MIONPs) were injected into tumours to a target dose of 5.5 mg Fe/cm3 tumour, and treated 24 h later by exposure to alternating magnetic field (AMF). Mice were randomly assigned to one of four cohorts to characterise (1) intratumour MIONP distribution, (2) effects of variable thermal dose mNPH (fixed AMF peak amplitude 24 kA/m at 160 ± 5 kHz) with/without RT (5 Gy), (3) effects of RT (RT5: 5 Gy; RT8: 8 Gy), and (4) fixed thermal dose mNPH (43 °C for 20 min) with/without RT (5 Gy). MIONP concentration and distribution were assessed following sacrifice and tissue harvest using inductively coupled plasma mass spectrometry (ICP-MS) and Prussian blue staining, respectively. Tumour growth was monitored and compared among treated groups. Results: LAPC-4 tumours retained higher MIONP concentration and more uniform distribution than did PC3 tumours. AMF power modulation provided similar thermal dose for mNPH and combination therapy groups (CEM43: LAPC-4: 33.6 ± 3.4 versus 25.9 ± 0.8, and PC3: 27.19 ± 0.7 versus 27.50 ± 0.6), thereby overcoming limitations of MIONP distribution and yielding statistically significant tumour growth delay. Conclusion: PC3 and LAPC-4 tumours represent two biological models that demonstrate different patterns of nanoparticle retention and distribution, offering a model to make comparisons of these effects for mNPH. Modulating power for mNPH offers potential to overcome limitations of MIONP distribution to enhance mNPH.",
keywords = "Hyperthermia, Magnetic nanoparticles, Prostate cancer, Radiation therapy, Radiosensitiser",
author = "Anilchandra Attaluri and Kandala, {Sri Kamal} and Michele Wabler and Haoming Zhou and Christine Cornejo and Michael Armour and Mohammad Hedayati and Yonggang Zhang and Theodore DeWeese and Cila Herman and Robert Ivkov",
year = "2015",
month = "6",
day = "1",
doi = "10.3109/02656736.2015.1005178",
language = "English (US)",
volume = "31",
pages = "359--374",
journal = "International Journal of Hyperthermia",
issn = "0265-6736",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Magnetic nanoparticle hyperthermia enhances radiation therapy

T2 - A study in mouse models of human prostate cancer

AU - Attaluri, Anilchandra

AU - Kandala, Sri Kamal

AU - Wabler, Michele

AU - Zhou, Haoming

AU - Cornejo, Christine

AU - Armour, Michael

AU - Hedayati, Mohammad

AU - Zhang, Yonggang

AU - DeWeese, Theodore

AU - Herman, Cila

AU - Ivkov, Robert

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Purpose: We aimed to characterise magnetic nanoparticle hyperthermia (mNPH) with radiation therapy (RT) for prostate cancer. Methods: Human prostate cancer subcutaneous tumours, PC3 and LAPC-4, were grown in nude male mice. When tumours measured 150 mm3 magnetic iron oxide nanoparticles (MIONPs) were injected into tumours to a target dose of 5.5 mg Fe/cm3 tumour, and treated 24 h later by exposure to alternating magnetic field (AMF). Mice were randomly assigned to one of four cohorts to characterise (1) intratumour MIONP distribution, (2) effects of variable thermal dose mNPH (fixed AMF peak amplitude 24 kA/m at 160 ± 5 kHz) with/without RT (5 Gy), (3) effects of RT (RT5: 5 Gy; RT8: 8 Gy), and (4) fixed thermal dose mNPH (43 °C for 20 min) with/without RT (5 Gy). MIONP concentration and distribution were assessed following sacrifice and tissue harvest using inductively coupled plasma mass spectrometry (ICP-MS) and Prussian blue staining, respectively. Tumour growth was monitored and compared among treated groups. Results: LAPC-4 tumours retained higher MIONP concentration and more uniform distribution than did PC3 tumours. AMF power modulation provided similar thermal dose for mNPH and combination therapy groups (CEM43: LAPC-4: 33.6 ± 3.4 versus 25.9 ± 0.8, and PC3: 27.19 ± 0.7 versus 27.50 ± 0.6), thereby overcoming limitations of MIONP distribution and yielding statistically significant tumour growth delay. Conclusion: PC3 and LAPC-4 tumours represent two biological models that demonstrate different patterns of nanoparticle retention and distribution, offering a model to make comparisons of these effects for mNPH. Modulating power for mNPH offers potential to overcome limitations of MIONP distribution to enhance mNPH.

AB - Purpose: We aimed to characterise magnetic nanoparticle hyperthermia (mNPH) with radiation therapy (RT) for prostate cancer. Methods: Human prostate cancer subcutaneous tumours, PC3 and LAPC-4, were grown in nude male mice. When tumours measured 150 mm3 magnetic iron oxide nanoparticles (MIONPs) were injected into tumours to a target dose of 5.5 mg Fe/cm3 tumour, and treated 24 h later by exposure to alternating magnetic field (AMF). Mice were randomly assigned to one of four cohorts to characterise (1) intratumour MIONP distribution, (2) effects of variable thermal dose mNPH (fixed AMF peak amplitude 24 kA/m at 160 ± 5 kHz) with/without RT (5 Gy), (3) effects of RT (RT5: 5 Gy; RT8: 8 Gy), and (4) fixed thermal dose mNPH (43 °C for 20 min) with/without RT (5 Gy). MIONP concentration and distribution were assessed following sacrifice and tissue harvest using inductively coupled plasma mass spectrometry (ICP-MS) and Prussian blue staining, respectively. Tumour growth was monitored and compared among treated groups. Results: LAPC-4 tumours retained higher MIONP concentration and more uniform distribution than did PC3 tumours. AMF power modulation provided similar thermal dose for mNPH and combination therapy groups (CEM43: LAPC-4: 33.6 ± 3.4 versus 25.9 ± 0.8, and PC3: 27.19 ± 0.7 versus 27.50 ± 0.6), thereby overcoming limitations of MIONP distribution and yielding statistically significant tumour growth delay. Conclusion: PC3 and LAPC-4 tumours represent two biological models that demonstrate different patterns of nanoparticle retention and distribution, offering a model to make comparisons of these effects for mNPH. Modulating power for mNPH offers potential to overcome limitations of MIONP distribution to enhance mNPH.

KW - Hyperthermia

KW - Magnetic nanoparticles

KW - Prostate cancer

KW - Radiation therapy

KW - Radiosensitiser

UR - http://www.scopus.com/inward/record.url?scp=84930977640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930977640&partnerID=8YFLogxK

U2 - 10.3109/02656736.2015.1005178

DO - 10.3109/02656736.2015.1005178

M3 - Article

C2 - 25811736

AN - SCOPUS:84930977640

VL - 31

SP - 359

EP - 374

JO - International Journal of Hyperthermia

JF - International Journal of Hyperthermia

SN - 0265-6736

IS - 4

ER -